ストックスクリーナーアプリを入手
27.80
3.91%
1.045
アフターアワーズ：
28.09
0.295
+1.06%
前日終値:
$26.75
開ける：
$27.22
24時間の取引高:
154.62K
Relative Volume:
0.79
時価総額：
$403.90M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-10.51%
1か月 パフォーマンス:
-7.99%
6か月 パフォーマンス:
+88.70%
1年 パフォーマンス:
-59.25%
1日の値動き範囲:
$25.93
$28.35
1週間の範囲:
$23.93
$33.06
52週間の値動き範囲:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
NGNE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
28.30 | 381.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.20 | 103.89B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.74 | 69.11B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.70 | 58.49B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
869.83 | 52.62B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
191.92 | 40.46B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | Craig Hallum | Buy |
| 2025-05-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | 開始されました | BMO Capital Markets | Outperform |
| 2024-06-11 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-29 | 開始されました | Leerink Partners | Outperform |
| 2024-03-21 | 開始されました | William Blair | Outperform |
| 2024-01-08 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-05 | 開始されました | Stifel | Buy |
| 2024-01-04 | 開始されました | TD Cowen | Outperform |
すべてを表示
Neurogene Inc (NGNE) 最新ニュース
Is Neurogene Inc. (UU8) stock cheap by valuation metricsJuly 2025 Gainers & Community Supported Trade Ideas - newser.com
Will Neurogene Inc. (UU8) stock beat international competition2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com
Signal strength of Neurogene Inc. stock in tech scannersMarket Risk Report & Risk Managed Investment Strategies - newser.com
Will Neurogene Inc. (UU8) stock keep high P E multiples2025 Key Highlights & AI Forecast for Swing Trade Picks - newser.com
Using AI based signals to follow Neurogene Inc.Market Risk Summary & Safe Entry Trade Signal Reports - newser.com
Will Neurogene Inc. stock outperform growth indexes2025 Risk Factors & Daily Chart Pattern Signals - newser.com
Is Neurogene Inc. (UU8) stock inflation resilientPortfolio Return Summary & Short-Term Trading Alerts - newser.com
Is Neurogene Inc. (UU8) stock a buy before new product rollout2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Is Neurogene Inc. stock a buy on dipsJuly 2025 Closing Moves & Free Safe Entry Trade Signal Reports - newser.com
Will Neurogene Inc. (UU8) stock profit from automation waveBull Run & Fast Momentum Entry Tips - newser.com
Applying big data sentiment scoring on Neurogene Inc.Rate Cut & Weekly Chart Analysis and Trade Guides - newser.com
Risk adjusted return profile for Neurogene Inc. analyzedWeekly Risk Summary & Weekly Momentum Picks - newser.com
Why Neurogene Inc. stock could outperform in 2025Earnings Overview Summary & Capital Protection Trade Alerts - newser.com
Why Neurogene Inc. stock remains undervaluedJuly 2025 Selloffs & Risk Controlled Daily Plans - newser.com
Why Neurogene Inc. (UU8) stock could be top winner2025 Dividend Review & Weekly Setup with ROI Potential - newser.com
How to use a screener to detect Neurogene Inc. breakoutsJuly 2025 Spike Watch & Accurate Buy Signal Alerts - newser.com
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Ironwood Pharma (IRWD) - The Globe and Mail
Why Neurogene Inc. stock is popular among millennialsTrade Signal Summary & Capital Efficient Trading Techniques - newser.com
Neurogene Doses First Patient in Registrational Trial of NGN-401 for Rett Syndrome - MarketScreener
Neurogene Positioned for Market Leadership with Advancements in Rett Syndrome Gene Therapy - TipRanks
Neurogene doses first patient in NGN-401 clinical trial - TipRanks
Neurogene Begins Dosing in Rett Syndrome Trial - TipRanks
Neurogene : 202511 NGNE Corporate Presentation FINAL - MarketScreener
[8-K] Neurogene Inc. Reports Material Event | NGNE SEC FilingForm 8-K - Stock Titan
Neurogene Inc. Announces First Participant Dosed in Embolden?? Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome - MarketScreener
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome - The Globe and Mail
Can Neurogene Inc. (UU8) stock sustain institutional flowsMarket Rally & AI Enhanced Execution Alerts - newser.com
Why Neurogene Inc. (UU8) stock could break out in 2025Weekly Gains Summary & Daily Stock Trend Watchlist - newser.com
Statistical indicators supporting Neurogene Inc.’s strengthExit Point & AI Driven Stock Movement Reports - newser.com
Will Neurogene Inc. stock reach all time highs in 2025Quarterly Growth Report & Technical Pattern Alert System - Fundação Cultural do Pará
Can a trend reversal in Neurogene Inc. lead to recoveryMarket Trend Review & Free Daily Entry Point Trade Alerts - newser.com
Is Neurogene Inc. stock attractive for retirement portfoliosWeekly Stock Report & Daily Volume Surge Signals - fcp.pa.gov.br
Why retail investors favor Neurogene Inc. stockJuly 2025 Technicals & Consistent Profit Trade Alerts - Fundação Cultural do Pará
Is Neurogene Inc. (UU8) stock among top earnings playsPortfolio Profit Report & Verified Swing Trading Watchlists - newser.com
Why Neurogene Inc. stock remains a top recommendationWeekly Market Summary & Real-Time Market Sentiment Reports - newser.com
What risks investors should watch in Neurogene Inc. stockWeekly Gains Report & Safe Entry Point Identification - Fundação Cultural do Pará
Volume spikes in Neurogene Inc. stock – what they meanJuly 2025 Action & Pattern Based Trade Signal System - newser.com
Is Neurogene Inc. (UU8) stock good for wealth creation2025 Sector Review & Low Drawdown Trading Techniques - fcp.pa.gov.br
Does Neurogene Inc. qualify in momentum factor screening2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Why Neurogene Inc. stock remains on watchlistsJuly 2025 Intraday Action & Stepwise Trade Signal Implementation - fcp.pa.gov.br
Neurogene (NASDAQ: NGNE) grants 1,185 stock option shares to new hire with 4-year vesting - Stock Titan
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Neurogene Inc (NGNE) 財務データ
Neurogene Inc (NGNE) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.05%
1.40%
大文字化:
|
ボリューム (24 時間):